NCT01206816View on ClinicalTrials.gov

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 4, 2010

Primary Completion Date

November 15, 2012

Study Completion Date

November 15, 2012

Conditions
Neoplasms
Interventions
DRUG

BI 6727 + BIBW 2992

BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day

Trial Locations (3)

Unknown

1230.20.32001 Boehringer Ingelheim Investigational Site, Brussels

1230.20.32003 Boehringer Ingelheim Investigational Site, Edegem

1230.20.32002 Boehringer Ingelheim Investigational Site, Ghent

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01206816 - An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours | Biotech Hunter | Biotech Hunter